Taking a Long-Term View of Merck (MRK): How to Interpret the Strength of Its Key Drugs and the “Waves” of Regulatory and Product Cycles

* This report is prepared based on data as of 2026-02-05.

What is MRK? (explained simply)

Merck & Company (MRK) researches and manufactures medicines that treat disease and vaccines that prevent it, then delivers them into healthcare systems worldwide. In pharma, the work doesn’t end when a product is made: meaningful value is created only after it clears government review (approval), maintains consistent quality and supply, and becomes embedded in how physicians and hospitals actually operate. MRK earns returns by running that full end-to-end cycle at scale over long periods of time.

Three pillars: human health, vaccines, and animal health

• Human pharmaceuticals (the largest pillar): Provides prescription medicines across oncology, immunology, cardiovascular, infectious disease, and more. Oncology, in particular, is the core growth engine.
• Vaccines (large but volatile): Products for immunization. Sales can swing by product depending on national and local vaccination programs, supply/demand dynamics, and policy impacts (HPV vaccines are a key example).
• Animal health: Medicines and vaccines for livestock and companion animals. The drivers differ from human healthcare, making it a separate earnings stream that can help balance the overall business.

Who are the customers, and how does it make money?

Customers broadly fall into: (1) hospitals and physicians (prescription drugs), (2) governments/public institutions and insurance systems (vaccine procurement and the pricing/reimbursement framework), and (3) veterinary clinics and livestock operators (animal health).

The revenue model is straightforward: the core is to sell proprietary drugs at attractive economics during the patent period. But no drug lasts forever, so creating the next blockbuster—through indication expansion and by supplementing the pipeline via acquisitions or partnerships—is itself part of the long-term earnings model.

What’s working now—and what could become the next pillars

The near-term engine remains the flagship oncology franchise. At the same time, MRK is clearly pushing to “build the next pillars,” and management highlights that contributions from newer products are rising. For long-term investors, this deserves as much attention as the flagship’s current strength.

Potential future pillars (important even if not yet the biggest revenue lines)

• New cardiovascular (cardiopulmonary) drugs (WINREVAIR, etc.): New products are already on the market, and trials/filings for label expansion are moving forward. If growth materializes, it could meaningfully reduce “oncology dependence.” In 2025, WINREVAIR grew to $1.44B.
• Infectious-disease “prophylactic drugs”: Through an acquisition, MRK added long-acting candidates designed to prevent influenza in a form distinct from vaccines. Built to deliver value in high-risk populations, this could become a new pillar if it plays out.
• New vaccine categories (pneumococcal vaccines, etc.): Vaccines can be volatile, but a broader lineup can improve overall stability. In 2025, the newer product CAPVAXIVE rose to $0.759B.

Internal capabilities that support competitiveness: manufacturing investment and AI adoption

• Expansion of manufacturing sites: MRK is making large-scale investments in manufacturing and R&D in the U.S., aiming to improve quality consistency, reduce supply disruption risk, and speed up new-product ramps.
• AI adoption in R&D: The company is using internal generative AI to accelerate clinical-trial document creation (for example, first drafts compressed from 2–3 weeks to 3–4 days). It is also partnering with external generative-AI drug discovery firms to apply proprietary data to small-molecule candidate design. The point isn’t to “sell AI,” but to raise productivity in discovery and development.

Reading the long-term pattern in the numbers: revenue trends steadily, profits swing more

MRK can look defensive as a pharma/vaccines business, but the historical record includes periods where profits (EPS and margins) move sharply year to year. In a Lynch-style framework, it’s most consistent to view MRK as a hybrid with cyclical characteristics—less tied to macro cycles and more driven by product lifecycles and policy/country-specific, event-driven waves.

Lynch’s six categories: MRK as a “hybrid leaning cyclical”

• Evidence (FY): Annual EPS shows wide peak-to-trough dispersion, such as 2010 0.28 → 2014 4.07 → 2023 0.14 → 2025 7.28.
• Margin volatility (FY): Operating margin fell to 4.9% in 2023, while 2025 was 41.2%.
• Smoothness of revenue (FY): Revenue rises over the long run (2015 39.5B → 2025 65.0B) and is less volatile than profits.

Long-term growth: revenue at a moderate pace, EPS faster

• EPS growth (FY, annualized): past 5 years +21.2%, past 10 years +16.7%
• Revenue growth (FY, annualized): past 5 years +9.4%, past 10 years +5.1%
• FCF growth (FY, annualized): past 5 years +12.7%, past 10 years +12.6% (however, FY2025 FCF is not sufficiently available, making it difficult to assess continuity in the most recent years based on this material alone)

Profitability (ROE and margins): strong recently, but down years exist in the history

• ROE (FY2025): 35.2% (high in the latest period)
• Operating margin (FY): 2023 4.9% → 2024 31.5% → 2025 41.2%
• Net margin (FY): 2023 0.6% → 2024 26.7% → 2025 28.1%

The most recent FY (2024–2025) looks like a strong profitability phase, but the longer series also includes years with extremely low ROE (e.g., 2010 1.6%, 2023 1.0%). That’s why it’s hard to simply label MRK a “steady growth stock.”

What drove EPS growth: revenue, margin recovery, and fewer shares

Over the past 5–10 years, EPS growth likely reflects a mix of revenue growth, the rebound from periods of depressed margins, and a gradual decline in shares outstanding. Shares outstanding fell from 2.841B in 2015 to 2.507B in 2025.

Near-term (TTM / roughly the latest 8 quarters): momentum is slowing, profitability is strong

Next, we check whether the long-term pattern is also showing up in the short term. On a TTM basis, revenue and EPS growth are running below mid-term averages, and momentum looks decelerating. At the same time, FY margins have improved sharply, creating a mixed setup: slower growth, but strong profitability.

EPS (TTM): positive growth, but moderate

• EPS (TTM): 7.34
• EPS (TTM YoY): +8.91%

Compared with the mid-term benchmark (FY 5-year EPS growth of +21.2%), the last year is clearly slower. With the last two years moving together, this reads less like “acceleration” and more like recovery/improvement at a moderate growth rate.

Revenue (TTM): roughly flat

• Revenue (TTM): 65.01B
• Revenue (TTM YoY): +1.31%

Versus the mid-term benchmark (FY 5-year revenue growth of +9.4%), the latest period is materially lower. That fits the hybrid profile: revenue trends gradually, while profits move more with specific drivers.

FCF (TTM): not assessable from this material alone

TTM free cash flow and its YoY change are not sufficiently available, so near-term momentum over the last year can’t be determined here. As context, the dataset includes items such as a 2-year FCF CAGR of +19.5% (annualized) and a trend correlation of +0.60 (tilting upward). But with TTM missing, it’s better to avoid firm conclusions about the last year.

Short-term profitability (FY): operating margin improved sharply

On an FY basis, operating margin jumped from 4.9% in 2023 to 31.5% in 2024 to 41.2% in 2025. Still, given MRK’s history of margin volatility, it’s safer not to frame this as “structural compounding every year,” and instead stick to what the data supports: profitability improved materially over the last three years.

Financial strength (including a bankruptcy-risk lens): strong coverage, leverage not stretched

For long-term pharma investing, the ability to fund R&D, manufacturing investment, M&A, and shareholder returns at the same time matters. Based on the latest FY data, MRK’s debt does not look like it would immediately constrain management, and interest coverage is solid.

• Net Debt / EBITDA (FY latest): 0.96x
• Interest coverage (FY latest): 16.69x
• Cash ratio (FY latest): 0.48

On these metrics, there’s no clear signal that bankruptcy risk should be a central concern. That said, given quarterly volatility, it’s appropriate to keep the conclusion narrow: there is no strong indication of rapid financial deterioration. Note that the latest debt-to-equity ratio is not sufficiently available and cannot be concluded from this material alone.

Dividends and capital allocation: long history is a plus, but near-term measurement is limited

MRK is a company where dividends are a meaningful part of shareholder returns, with 36 consecutive years of dividends and 13 consecutive years of dividend increases (the last year with a dividend cut or a pause in increases was 2011). That’s hard for income-focused investors to ignore.

Yield and dividend growth: historical averages are available, but the latest TTM is unclear

• 5-year average dividend yield: 3.42%
• 10-year average dividend yield: 4.60%
• Latest TTM dividend yield: not sufficiently available and cannot be confirmed from this material alone

Historically, the dividend yield has often sat in a range investors pay attention to. However, due to data constraints, we can’t judge whether the latest TTM yield is above or below historical norms.

Dividend per share growth: a pattern of steady, moderate increases

• 5-year dividend per share growth: +6.93% annualized
• 10-year dividend per share growth: +5.58% annualized

The dataset shows a TTM YoY change in dividend per share of -44.72%, but the latest TTM dividend per share level itself cannot be confirmed within the same material. As a result, it’s best not to over-interpret that YoY figure alone as proof that “the dividend actually declined.”

Dividend safety: exposed to earnings volatility, and near-term cash coverage can’t be verified

• Earnings-based payout ratio (5-year average): 4.54x (mechanically tends to spike in years when earnings fall)
• Earnings-based payout ratio (10-year average): 2.88x
• Latest TTM payout ratio, FCF, and FCF dividend coverage: not sufficiently available and cannot be confirmed from this material alone

On an FY basis, FCF margin has remained positive over the long run, and FY2024 FCF margin is 28.2%, but FY2025 FCF is not sufficiently available. Overall, it’s reasonable to view dividend safety as moderate—without calling it exceptionally strong or clearly unstable—and to note that short-term dividend coverage can’t be quantified here.

Limits on peer comparison

Because peer data isn’t included, relative positioning versus the industry can’t be determined from this material. The only takeaway here is that historical average yield has been around the 3% range (5 years) and 4% range (10 years), suggesting dividends have been a meaningful part of the historical investment case.

Where valuation sits vs. MRK’s own history (6 metrics)

Here we look only at where MRK stands within its own historical distribution (primarily the past 5 years, with the past 10 years as context), rather than versus the market or peers. Where FY and TTM differ, we treat that as a period-definition effect.

PEG: above the 5-year and 10-year historical ranges

• PEG (at $108.34 share price): 1.66x
• Past 5-year normal range (20–80%): 0.10–0.61x (above this)
• Past 10-year normal range (20–80%): 0.07–0.88x (also above this)

On a growth-adjusted basis, the current level is high relative to MRK’s own historical range (i.e., above the range).

P/E: toward the low end of the 5-year range, and below the 10-year midpoint

• P/E (TTM, at $108.34 share price): 14.77x
• Past 5-year normal range (20–80%): 12.94–22.94x (toward the low end within the range)
• Past 10-year central level: 18.89x (below this)

The earnings multiple does not look clearly overheated versus MRK’s own history. At the same time, given low TTM revenue growth of +1.31% and the possibility that profit volatility returns, it’s also plausible the market is discounting those risks as part of the narrative (without asserting that it is).

Free cash flow yield: historical range is visible, but the current level can’t be confirmed

• FCF yield (TTM): not sufficiently available and cannot be confirmed
• Past 5-year normal range (20–80%): 4.04%–7.02%
• Past 10-year normal range (20–80%): 4.97%–9.30%

Even though the historical distribution is available, the current (TTM) value can’t be confirmed here, so we can’t judge whether it’s within, above, or below the range.

ROE: near the top end of the historical range

• ROE (FY latest): 35.17%
• Past 5-year normal range (20–80%): 25.45%–35.53% (near the upper bound)

Capital efficiency is currently high—near the upper bound of the past 5-year and 10-year distributions.

Free cash flow margin: historical range is visible, but the current level can’t be confirmed

• FCF margin (TTM): not sufficiently available and cannot be confirmed
• Past 5-year normal range (20–80%): 14.85%–25.49%
• Past 10-year normal range (20–80%): 14.85%–26.02%

As with FCF yield, because TTM can’t be confirmed, it’s difficult to assess the current level or the direction over the last two years from this material alone.

Net Debt / EBITDA (inverse indicator): near the low end of the historical range (= lower is better)

Net Debt / EBITDA is an inverse indicator where lower values (including negative) generally imply more cash flexibility and a lighter financial burden.

• Net Debt / EBITDA (FY latest): 0.96x
• Past 5-year normal range (20–80%): 0.94–2.81x (near the lower bound)
• Past 10-year normal range (20–80%): 0.97–1.68x (near the lower bound)

This sits near the low end of MRK’s historical distribution, and the direction over the last two years also points toward lower leverage.

Cash flow tendencies: alignment between EPS and FCF can’t be verified near term

For long-term investors, it’s natural to want to confirm that rising accounting earnings (EPS) are matched by cash generation (FCF). For MRK, however, near-term TTM data for FCF, FCF margin, and FCF yield is not sufficiently available, so this material alone can’t confirm whether recent profitability is backed by cash.

That said, on an FY basis, the dataset shows FCF growth (both past 5 years and 10 years in the ~+12% annualized range) and FY2024 FCF margin of 28.2%, pointing to a long history of positive cash generation. Distinguishing “business deterioration” from “investment or timing effects” remains an important follow-up that requires additional data.

Why MRK has succeeded (the core of the story)

MRK’s intrinsic value is its ability to take prescription drugs and vaccines—products that only truly work when “regulation, clinical evidence, manufacturing quality, and commercial distribution” are all in place—and deploy them globally at scale. In healthcare, customers evaluate not just efficacy but also safety, supply reliability, and appropriate-use workflows, making this a structurally high-barrier arena.

Product-level “strength” and “volatility”

• Flagship oncology immunotherapy: Grew to $31.68B in 2025 (+7% YoY), the company’s primary engine.
• Flagship vaccines (HPV, etc.): Fell sharply to $5.23B in 2025 (-39% YoY), underscoring sensitivity to policy, inventory, and country-specific factors.
• Animal health: Grew +8% in 2025 and can help offset volatility at the company level because its demand drivers differ from human health and vaccines.

This combination—high barriers to entry alongside product-by-product volatility—fits the long-term profile where profits can swing meaningfully even when revenue looks comparatively steady.

Is the thesis still intact? (checking against recent developments)

One notable recent shift is that vaccines (especially HPV) are being discussed less as a growth engine and more as a business in an adjustment phase driven by country-specific factors. With softer demand in China and rising channel inventory, MRK paused shipments and prioritized inventory drawdown. Separately, it has been reported that updates to U.S. vaccination recommendations could potentially affect demand planning for 2026.

Meanwhile, the flagship oncology franchise still grew +7% in 2025, and the central thesis—anchor on the flagship while building the next pillars through new products—remains intact. The current framing is essentially: the flagship is holding up, but vaccine volatility is weighing on the company’s overall growth trajectory.

Quiet Structural Risks: eight issues behind the strength

The goal here isn’t to claim anything is already breaking, but to surface structures that could break. In long-term investing, spotting “cracks” before they show up in reported numbers can matter.

• 1) Product concentration risk: The flagship oncology immunotherapy was $31.68B in 2025, a large share of total revenue of $65.01B. Efficient when strong, but the downside can be meaningful if it slows.
• 2) Approaching patent expiry and pricing regimes: As patent cliffs, biosimilars, and government price negotiations approach, the flagship’s slope can steepen. The risk is visible well in advance, but can bite later if replacements are delayed.
• 3) Shifts in the main battlefield for differentiation: In oncology immunotherapy, competition can extend beyond efficacy into dosing format, combination regimens, and operational execution—potentially forcing a refresh of the winning playbook.
• 4) Supply chain / distribution dependence (vaccines): As seen in China, where inventory adjustments led to shipment halts, demand and channel inventory management can distort how the overall company is perceived.
• 5) Organizational culture wear: Reorganization and cost optimization could impair R&D speed, morale, and decision quality. It often shows up first in non-financial indicators (hiring, attrition, development delays).
• 6) Early signs of profitability deterioration: Recent FY results are highly profitable (2025 operating margin 41.2%), but the past includes major down years. The key is whether the start of deterioration can be detected early.
• 7) Rising financial burden: Interest coverage is 16.7x and Net Debt/EBITDA is just under ~1x, so it doesn’t look stretched today. Still, it could become a secondary risk if large acquisitions coincide with flagship deceleration.
• 8) Changes in industry structure: The competitive dynamics of drug discovery may shift, and emerging players could reshape the landscape. Over time, the industry’s “how to produce new drugs” will be tested more intensely.

Competitive landscape: less “company vs. company,” more “therapy area × product × policy”

Large-cap pharma has high barriers to entry, but substitution waves—patent expiry, same-class competitors, and next-generation modalities (ADCs, bispecific antibodies, cell therapies, etc.)—inevitably arrive. In practice, competition is best analyzed by therapeutic area rather than at the consolidated company level.

Key competitors (players often compared at the company level)

• Bristol Myers Squibb（BMY）
• Roche（RHHBY）
• AstraZeneca（AZN）
• Pfizer（PFE）
• GSK（GSK）
• Zoetis（ZTS）
• Elanco（ELAN）

Therapeutic-area competition map (what determines winners and losers)

• Oncology immunotherapy: Beyond same-class comparisons, combinations, line of therapy, biomarkers, and dosing/operational design become key competitive axes. Once embedded in standard of care, switching tends to be slower.
• HPV vaccines: Beyond scientific value, national procurement/recommendations/dose schedules, supply, and channel inventory directly drive sales. In China, local 9-valent HPV has emerged at lower prices and could create pricing pressure.
• Cardiopulmonary (PAH: WINREVAIR): Adoption depends on whether it is layered on top of existing therapy or replaces it. Outcomes, safety, and practical dosing/operations matter. While outcome improvements have been reported recently, confirming advantage should wait for evidence in adoption, reimbursement, and real-world execution.
• Animal health: Portfolio breadth, sales/distribution reach, and reliable manufacturing supply are key competitive factors. Demand drivers differ from human healthcare.

Competition-related KPIs investors should monitor

• Oncology: Positioning in first-line therapy (guidelines and real-world practice), approvals and uptake of combination strategies, and where next-generation modalities are intensifying competition.
• HPV: Timing of channel inventory normalization in China; pricing/supply capacity and policy adoption of local 9-valent products; impact of changes in vaccination recommendations (doses and target populations).
• PAH: WINREVAIR adoption pace (add-on vs. replacement), improvements in incumbent therapies, and progress of new candidates.
• Animal health: Growth by livestock vs. companion animals, and differences in manufacturing investment and supply capacity among leading players.
• Company-wide: How much new-product ramps dilute flagship dependence, and development velocity (time compression from trial start → approval → label expansion).

Moat and durability: strong barriers, but the source shifts with product lifecycles

MRK’s moat is rooted in the layered barriers of a regulated industry—regulatory capability, quality systems, manufacturing, supply, reimbursement, and operational execution—plus the accumulation of long-term data (clinical, safety, manufacturing). In pharma, however, the moat is often strongest not at the company level but when a specific product is embedded in standard of care or standard vaccination. During transition periods, the moat’s center of gravity tends to shift from “the product” toward “R&D hit rate and commercialization execution.”

AI-era positioning: more tailwind than headwind, but competition speeds up for everyone

MRK isn’t selling AI infrastructure (compute or foundation models). It’s closer to an application-oriented integrator, embedding AI into day-to-day pharma development workflows. Overall, AI is less likely to substitute MRK’s core value and more likely to compress bottlenecks in R&D, clinical development, documentation, and decision-making—showing up as differences in hit rate and speed that translate into competitive advantage.

• Network effects: Limited (value doesn’t scale exponentially with user count).
• Data advantage: Strong (AI can leverage accumulated clinical, safety, manufacturing, and regulatory data).
• AI integration: Advancing at the process level (e.g., significant compression of clinical document creation).
• Mission criticality: Very high (directly tied to medical outcomes and policy operations, with high switching costs).
• Barriers to entry: High, though AI could compress them somewhat (more industry-wide iteration increases competitive speed).
• AI substitution risk: Low for the core value, though peripheral work will be automated (useful as process compression).

Management and culture: staying R&D-led while pairing optimization with reinvestment in 2025

The CEO (Robert M. Davis) consistently communicates an R&D-led posture: saving lives and improving quality of life through leading-edge science. A major recent move is that in 2025 the company paired multi-year cost reductions (on the order of $3B annually) with reinvestment into the pipeline and new-product launches. The approach includes reducing headcount across administrative functions, sales, and some R&D roles, while hiring in growth areas and optimizing sites and the manufacturing network.

Is this consistent with the success story?

The underlying narrative is: the flagship is strong, vaccine volatility is weighing on the growth trajectory, and MRK is working to cultivate multiple next pillars to dilute flagship dependence. Read that way, the optimization program looks less like a retreat from R&D and more like a commitment to reallocate resources (people, capital, sites) to match a portfolio transition.

The cultural duality (could cut either way)

• Path to a positive outcome: Clearer priorities and sharper focus; manufacturing optimization that improves supply stability and ramp speed.
• Path to a negative outcome: Reorganization creating a defensive mindset or on-the-ground shrinkage, with potential knock-on effects to R&D speed and hit rate.

For long-term investors, what matters more than the elegance of the plan is execution precision—who is reduced, where talent is redeployed, and where hiring continues—which will determine whether there is unseen wear and tear.

Understanding MRK through a KPI tree: where value is created—and where it can stall

Ultimate outcomes

• Long-term earnings growth (compounding EPS)
• Cash generation (balancing investment and shareholder returns)
• Capital efficiency (whether high ROE persists)
• Financial endurance (whether debt constrains flexibility)

Intermediate KPIs (Value Drivers)

• Revenue scale and growth
• Product mix (degree of flagship concentration and share of new products)
• Profitability (level and volatility of operating and net margins)
• R&D productivity (new-drug creation, development speed, label expansion)
• Commercialization and supply execution (quality, supply stability, global rollout)
• Capital allocation (dividend continuity, share count reduction, reinvestment and optimization)
• Financial leverage management (interest coverage capacity, debt burden)

Constraints and bottleneck hypotheses (Monitoring Points)

• Regulatory/approval timelines and manufacturing/quality/supply constraints determine ramp speed.
• Policy, reimbursement, and recommendation changes reshape demand planning and create operational friction.
• Country-level demand and inventory adjustments (especially vaccines) can disrupt short- to mid-term smoothness.
• Flagship concentration structurally increases volatility.
• Updates to competitive rules (same-class drugs, next-generation modalities, price competition) change what “differentiation” means.
• Side effects of organizational restructuring can impair R&D speed, morale, and decision quality (impact not asserted).
• Cash-generation observability constraints: near-term FCF-related (TTM) data is insufficient, making it hard to verify with the same granularity.
• Bottlenecks to watch: the pace at which flagship dependence declines; whether vaccine volatility reflects “demand destruction” or “adjustment”; whether new pillars compound in a sustained way; whether AI-driven process compression is repeatable; whether supply investment relieves bottlenecks; whether optimization is creating wear and tear; whether financial flexibility is preserved; and whether profit volatility is driven more by revenue or by profitability.

Two-minute Drill: a long-term framework for evaluating MRK

• MRK earns returns through an execution engine that integrates not just efficacy, but also regulation, clinical evidence, quality, supply, reimbursement, and operational execution to deliver drugs and vaccines into real-world care.
• The financial profile isn’t purely defensive; it’s a hybrid with cyclical characteristics, where profits can swing with product lifecycles and policy/country-specific factors.
• Recently, FY profitability is strong (operating margin 41.2%, ROE in the mid-30% range), but TTM revenue growth is +1.31% and EPS growth is +8.91%, so momentum looks slower than mid-term averages (period-definition effects may contribute to differences in appearance).
• The biggest hard-to-see issue is that flagship concentration (oncology immunotherapy) and HPV vaccine volatility tied to policy, inventory, and country-specific factors can distort the company’s overall growth trajectory.
• The long-term path to winning can be summarized as cultivating multiple next pillars (cardiopulmonary, etc.) to connect earnings peaks, and embedding process compression—including AI—into operations to increase development and launch velocity.
• At the same time, if restructuring and cost optimization reduce R&D speed or morale, competitiveness can erode before it shows up in reported numbers—so monitoring should include non-financial signals as well.